Kathy Lee-Sepsick is the founder of Femasys, established in February 2004. She brings more than 30 years of leadership in the medical technology industry with a strong track record of building and scaling emerging companies, advancing innovative product pipelines, and leading organizations through commercialization and growth. Ms. Lee-Sepsick holds over 200 global patents covering Femasys’ products and candidates, reflecting her longstanding commitment to innovation in women’s health. Prior to founding Femasys, she held strategic and operational roles across multiple company life cycles, including at Novoste Corporation, a pioneer in intravascular brachytherapy, and SaluMedica, a biomaterials company focused on artificial cartilage technologies. Earlier in her career, she managed product strategy at Terumo Medical Corporation, collaborating closely with Boston Scientific on interventional products across multiple specialties, including cardiovascular, peripheral vascular, neurovascular, and gastrointestinal. Ms. Lee-Sepsick earned a BS in Biochemistry and an MBA from Rutgers University.